Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(3.53)
# 839
Out of 5,154 analysts
35
Total ratings
57.14%
Success rate
28.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Reiterates: Overweight | n/a | $173.30 | - | 5 | May 15, 2025 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $3.32 | - | 4 | May 15, 2025 | |
| INSM Insmed | Reiterates: Overweight | n/a | $140.13 | - | 8 | Feb 20, 2025 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $3.34 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint | Reiterates: Overweight | n/a | $15.75 | - | 6 | Jun 20, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $1.61 | +24.22% | 2 | Aug 31, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $8.13 | +305.90% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $1.78 | +152.81% | 2 | May 17, 2023 | |
| AYTU Aytu BioPharma | Maintains: Overweight | $220 → $100 | $2.52 | +3,868.25% | 2 | May 17, 2022 |
Belite Bio
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $173.30
Upside: -
Precigen
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.32
Upside: -
Insmed
Feb 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $140.13
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.34
Upside: -
EyePoint
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.75
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $1.61
Upside: +24.22%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $8.13
Upside: +305.90%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $1.78
Upside: +152.81%
Aytu BioPharma
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $2.52
Upside: +3,868.25%